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cense.Abstract Background: Osteoarthritis (OA); the most common joint disease, is not only character-
ized by cartilage destruction; but also by alteration of bone and synovial tissue metabolism, though
their relative importance in the initiation and progression of OA is still debated. To identify patients
with a high risk for destructive OA, more sensitive techniques than plain X-rays are needed.
Aim of the work: To study the diagnostic and prognostic value of some biochemical markers
serum hyaluronic acid (HA) and serum cartilage oligomeric matrix protein (COMP), high sensitive
C-reactive protein (hs-CRP) in the included patients had early OA knees and their relation to dis-
ease progression.
Patients and methods: Sixty patients had early knee OA and 20 control subjects were included.
WOMAC index, laboratory investigations (COMP, HA, hs-CRP) and radiological evaluation
(Kellgren and Lawrence grading scale and Thomas compartmental score) were performed for each
patient at baseline and after one year.
Results: HA was signiﬁcantly higher in patients than controls (p> 0.001) with the highest spec-
iﬁcity and positive predictive value. It was signiﬁcantly correlated with COMP at baseline and after
one year (p= 0.01). The levels of HA at baseline correlated with its levels after one year
(p> 0.001). It also correlated with K–L grading score (p= 0.02). COMP was signiﬁcantly higher
in patients than controls (p> 0.001). It was signiﬁcantly correlated with Thomas score after one(A.F. Darwish).
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2 A.F. Darwish et al.year (p= 0.007). Baseline levels of COMP correlated signiﬁcantly with its levels after one year
(p= 0.005). The differences of the serum levels of hs-CRP at the baseline evaluation and after
one year between patients and controls were not statistically signiﬁcant (p= 0.4, 0.5, respectively).
Conclusions: The measurements of HA and COMP may be of diagnostic and prognostic value in
differentiating patients with early joint destruction and in determining disease progression. A single
biochemical marker has deﬁnitive diagnostic value and the combination with other biochemical
markers as well as with clinical and radiographic data would most likely help to improve the clinical
assessment of patients. Serum hs-CRP is not a good predictor of individual patient progression and
has a poor sensitivity and speciﬁcity.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Osteoarthritis (OA) is deﬁned by focal lesions of the articular
cartilage, combined with a hypertrophic reaction (sclerosis)
in the subchondral bone and new bone formation (osteo-
phytes) at the joint margins. More recently, OA has been
relabelled as a whole organ disease because pathological
abnormalities such as periarticular muscle weakness, lax lig-
aments, low grade synovitis, meniscal degeneration and neu-
rosensory system alteration are frequently present in these
patients [1].
To identify patients with a high risk for destructive OA and
to monitor drug efﬁcacy, more sensitive techniques than plain
X-rays are needed. Speciﬁc and sensitive biochemical markers
reﬂecting abnormalities of the turnover of bone, cartilage, and
synovial tissues may be useful for the investigation and moni-
toring of OA [2].
Good approaches in the treatment of OA increase the need
for measurable standard for disease progression. One or two
years are needed to observe changes in plain radiographs
whereas few months are sufﬁcient to observe changes in bio-
chemical markers [3]. Early diagnosis of OA and assessment
of disease severity are other potential uses for these markers
[4]. Serum cartilage oligomeric matrix protein (COMP) and
serum levels of HA have the potential to be a prognostic mar-
ker of disease progression [5,6].
COMP was the foremost biomarker among investigated
biomarkers. It could be continuously expressed and predicted
knee OA progression. [26]. Serum levels of HA had a predic-
tive value for further development of knee OA in that further
joint space narrowing was detected in patients with knee OA
[6].
We aimed to study the diagnostic and prognostic value of
some biochemical markers; HA and COMP, hs-CRP in the in-
cluded patients had early OA knees and their relation to dis-
ease progression.2. Patients and methods
Sixty OA patients diagnosed by the American College of
Rheumatology (ACR) clinical and radiographic criteria for
knee OA [7], and 20 control subjects matched for age and
sex were included in the present study. The patients were re-
cruited over 6 months at the Rheumatology and Rehabilita-
tion Outpatient Clinic, Minia University Hospital. Follow-up
was done after one year for each patient from ﬁnishing the
recruitment.2.1. Inclusion criteria
Patients with primary knee OA unilateral or bilateral.
Patients less than 50 years with chronic knee pain more
than three months and radiological evidence of early
OA.
2.2. Exclusion criteria
Patients with secondary OA, e.g. post-traumatic or post-
inﬂammatory, e.g. rheumatoid arthritis (RA).
Patients with systemic diseases as renal or hepatic failure.
Patients with generalized OA or patients with concomitant
knee and hip OA.
Patients with cervical or lumbar spondylosis.
All patients were subjected to: full history, clinical examina-
tion, laboratory investigations and radiological examination at
the start of the study and after one year according to the
following.
2.3. Clinical evaluation
Assessment of pain was done using Numerical Rating Scale of
Pain [8].
2.4. Functional evaluation
Functional evaluation of the patient was done using Arabic
translated and validated version of Western Ontario and
McMaster University (WOMAC) index [9].
2.5. Radiological evaluation
Anteropoterior radiographs were taken to the patients in
the supine position, in standing (weight bearing position)
with the knee ﬂexed by 20, and a skyline view was taken
for assessment of patellofemoral compartment. Radiological
evaluation was done to all patients by two methods: Kell-
gren–Lawrence grading scale (1957). For categorization of
the patients to four categories at baseline and for correlat-
ing it with clinical and laboratory parameters, as it is the
gold standard in all clinical trials. It was not done after
one year as for a patient to progress by one grade K–L
it needs two or more years [10].
Thomas grading scale (1975): It is compartmental evaluation
for knee OA used as a scoring system for joint space narrowing,
subchondral sclerosis, subchondral cysts and osteophyte. Each
Table 1 Clinical data of patients at baseline evaluation.
Range Mean ± SD
Disease duration (years) 0.5–20 4 ± 3.8
Age at onset (years) 42–70 54.9 ± 6.8
Morning stiﬀness (minutes) 0–15 9.7 ± 5.4
Inactivity stiﬀness 0–10 5.8 ± 2.9
BMI 20.7–55.8 28.6 ± 8
NRSP 3–10 6.8 ± 1.7
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each compartment, e.g. right and leftmedial compartment, right
and left lateral compartment, right and left patellofemoral com-
partment. Then the total score was calculated by summation of
the three compartments. This score was used for sensitive corre-
lations with clinical and laboratory parameters, for compart-
mental evaluation, and for detection of disease progression. It
was done at baseline and after one year. Remodeling, intra-
articular calciﬁcation, periarticular calciﬁcation, sublaxation
and femoral cortical erosion were recorded as present or absent.
X-rays were evaluated by three observers two of them were
ﬁxed, two of the observers were blinded to the condition of the
patients and whether it is the baseline or the follow-up examina-
tion [11].
2.6. Laboratory evaluation
The following routine and special laboratory tests were done
for all patients and control subjects at baseline and after one
year. Complete blood count, erythrocyte sedimentation rate
(ESR) (by Westergren method), liver and renal function tests
were done for exclusion of renal or hepatic patients.
2.7. Biochemical markers
Synovial inﬂammation markers: serum hyaluronic acid (HA)
by ELISA: The HA test kit is an enzyme-linked binding pro-
tein assay that uses a capture molecule known as hyaluronic
acid binding protein (HABP) [12]. Normal range = 0–75 ng/
mL. Values more than 75 ng/mL were reported to be positive.
Hs-C reactive protein (CRP) was done using the high sensitiv-
ity enzyme immunoassay (hs-CRP ELISA) for quantitative
determination of CRP concentration. Values more than
8.2 mg/L were reported to be positive.
2.8. Cartilage marker
Serum cartilage oligomeric matrix protein (COMP). COMP
ELISA is a solid-phase, two-site enzyme immunoassay. Value
<12 U/L lower risk of aggressive joint destruction (negative),
or >12 U/L increasing risk of aggressive joint destruction
(positive).
Data were coded, entered and analyzed by the statistical
Package for the Social Sciences (SPSS for windows version
11.0) SPSS Inc., 2001. Two-tailed tests were used throughout
and statistical signiﬁcance was set at the conventional 0.05 le-
vel. Group comparisons were done by Student’s t-test to com-
pare the means of two groups of cases and chi-squared (v2)
test, to test the signiﬁcance of the differences between the
two groups in categorical variables. Correlations was done
by the bivariate Spearman correlation coefﬁcient. Positive
and negative predictive values were calculated and reported.
WOMAC 6–88 52.2 ± 17.8
Number Percent
Click 52 86.7
Muscle wasting 45 75
Knee instability 44 73.3
Knee swelling 32 53.3
Deformity 15 25
BMI = Body Mass Index, NRSP = Numerical Rating Scale of
Pain, WOMAC=Western Ontario and McMaster University.3. Results
3.1. Demographic data and clinical features
This study included 60 OA patients underwent clinical assess-
ment, radiological examination and laboratory evaluation at
baseline and after one year. It also included 20 control sub-
jects. The age of the patients ranged from 44 to 79 years witha mean of 58.9 ± 7.7 years. Male patients were 48.3% while
female patients were 51.7%. The control group was age and
sex matched. The disease duration ranged from 0.5 to 20 years
with a mean of 4 ± 3.8 years. Age of onset ranged from 42 to
70 years with a mean of 54.9 ± 6.8 years. Morning stiffness
ranged from 0 to 15 min with a mean of 9.7 ± 5.4 min while
inactivity stiffness ranged from 0 to 10 min with a mean of
5.8 ± 2.9 min. BMI of the patients ranged from 20.7 to 55.8
with a mean of 28.6 ± 8. Numerical Rating Scale of Pain
(NRSP) at baseline ranged from 3 to 10 with a mean of
6.8 ± 1.7. WOMAC index at baseline ranged from 6 to 88
with a mean of 52.2 ± 17.8, the prevalence of other clinical
ﬁndings obtained by history taking, other than pain at baseline
evaluation were reported in Table 1. Physical ﬁndings in knee
examination at baseline evaluation and after one year for each
knee are shown in Table 2.
Fig. 1 and Table 3 show radiological evaluation of patients
at baseline.
3.2. Compartmental evaluation at baseline and after one year by
Thomas score
Thomas score at baseline ranged from 8 to 45 with a mean of
28.3 ± 7.7. After one year it ranged from 10 to 58 with a mean
of 31.5 ± 9.4. The difference was very highly signiﬁcant
(p> 0.001) Fig. 2. Patients who had increased Thomas score
after one year were deﬁned as radiological progressors were
40 patients (66.7%), and the non-progressors were 20 patients
(33.3%).
Biochemical and inﬂammatory markers difference between
patients group and control group at the baseline and after one
year.
Qualitative hs-CRP, ESR (ﬁrst hour), quantitative and
qualitative HA, quantitative and qualitative serum COMP lev-
els at the baseline were highly signiﬁcant in patients than con-
trol (p= 0.009, p= 0.03, p> 0.001, p> 0.001, p> 0.001 and
p > 0.001, respectively). This signiﬁcant difference between
patient group and control group was detected after one year
except hs-CRP (p= 0.2, p= 0.03, p > 0.001, p > 0.001,
p= 0.005 and p= 0.004, respectively), Tables 4 and 5.
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Figure 2 Compartmental evaluation at baseline and after one
year by Thomas score.
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Figure 1 Percent of cases with different grades of K–L. (Fig. 1
and Table 3 show radiological evaluation of patients at baseline.)
Table 3 Compartmental evaluation by Thomas score in
patients at baseline.
Range Mean ± SD
Medial compartment 4–19 10.7 ± 3.3
Lateral compartment 2–17 8.8 ± 3.1
Patellofemoral compartment 0–14 8.8 ± 2.7
Total score 8–45 28.3 ± 7.7
Table 2 Physical ﬁndings in knee examination at baseline evaluation and after one year.
Knee examination at baseline Knee examination after one year
Left knee Right knee Left knee Right knee
Number (%) Number (%) Number (%) Number (%)
Crepitus 59 (98.3%) 55 (91.7%) 60 (100%) 59 (98.3%)
Tenderness 57 (95%) 50 (83.3%) 52 (86.7%) 50 (83.4%)
Hamstring spasm 38 (63.3%) 34 (56.7%) 31 (51.7%) 29 (48.3%)
Synovitis 31 (51.7%) 18 (30%) 26 (43.3%) 21 (35%)
Pes anserine bursitis 31 (51.7%) 25 (41%) 25 (41.7%) 19 (31.7%)
Flexion deformity 21 (35%) 18 (30%) 20 (33.3%) 17 (28.3%)
Baker cyst 12 (20%) 12 (20%) 9 (15%) 10 (16.7%)
Site of tenderness
No 3 (5%) 10 (16.7%) 8 (13.3%) 10 (16.7%)
Medial 15 (25%) 13 (21.7%) 15 (25%) 16 (26.7%)
Lateral 1 (1.7%) 0 (0%) 0 (0%) 0 (0%)
Anterior 5 (8. 3%) 5 (8.3%) 5 (8.3%) 5 (8.3%)
Posterior 3 (5%) 0 (0%) 2 (3.3%) 0 (0%)
All 33 (55%) 32 (53.3%) 30 (50%) 29 (48.3%)
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HA, hs-CRP and serum COMP in patients at baseline and
after one year. It didn’t show signiﬁcant difference regarding
serum HA (p= 0.5) and hs-CRP (p= 0.3), while the differ-
ence of serum COMP was very highly signiﬁcant (p> 0.001).
Table 7 shows no statistically signiﬁcant differences of the
serum levels of hs-CRP at the baseline evaluation and after
one year between patients and controls (p= 0.4 and 0.5,
respectively).
3.3. Correlations
The correlations between serum COMP levels qualitatively
and quantitatively, at baseline and after one year showed sig-
niﬁcance with variable degrees and serum HA titers at baseline
were highly signiﬁcantly correlated with HA titers after one
year (p> 0.001).
COMP at baseline correlated signiﬁcantly with qualitative
CRP at baseline (p= 0.005), with HA titer at baseline and
after one year (p= 0.01), with qualitative HA at baseline
(p= 0.05) and after one year (p= 0.004). COMP after one
year correlated only with qualitative HA after one year
(p= 0.01).Age of the patients signiﬁcantly correlated with the pres-
ence of synovitis after one year, i.e. older patients had higher
prevalence of synovitis, and with Kellgren–Lawrence index
(p= 0.02, 0.04, respectively). Age at onset correlated with
presence of synovitis after one year (p= 0.02).
Kellgren–Lawrence index was signiﬁcantly correlated with
qualitative HA at baseline (p= 0.02) (Fig. 3). Thomas score
after one year correlated signiﬁcantly with COMP titer after
one year (p= 0.007).
Figure 3 Correlation between K–L grade and HA at baseline.
Table 4 Quantitative and qualitative serum COMP and serum HA in patients and control group at baseline.
Serum COMP Serum HA
Quantitative Range Mean ± SD p Range Mean ± SD p
Patients 4–32 16.2 ± 6.3 >0.001** 5–800 131.8 ± 171.3 >0.001**
Control 1–17.8 8.4 ± 4.2 5–65 27.2 ± 15.2
Qualitative Number Percent Number Percent
Patients 42 70 >0.001** 25 41.7 >0.001**
Control 4 20 0 0
Table 5 Quantitative and qualitative serum COMP and serum HA in patients and control group after one year.
Serum COMP Serum HA
Quantitative Range Mean ± SD p Range Mean ± SD p
Patients 1–32 12.2 ± 7 0.005** 15–800 145.3 ± 205.6 >0.001**
Control 1–17.8 8.4 ± 4.2 5–65 27.2 ± 15.2
Qualitative Number Percent Number Percent
Patients 35 58.3 0.004** 23 38.3 >0.001**
Control 4 20 0 0
Table 6 Comparison between quantitative serum HA, hs-
CRP and serum COMP in patients at baseline and after one
year.
Range Mean ± SD p
Quantitative HA
Baseline 5–800 131.8 ± 171.3 0.5
After one year 15–800 145.3 ± 205.6
Quantitative COMP
Baseline 4–32 16.2 ± 6.3 >0.001**
After one year 1–32 12.2 ± 7
Quantitative hs-CRP
Baseline 3–450 35.7 ± 65.1 0.3
After one year 3–200 29.5 ± 43.4
Table 7 Quantitative hs-CRP in patients and controls at
baseline evaluation and after one year.
Range Mean ± SD p
Hc-CRP at baseline
Patients 3–450 35.7 ± 65.1 0.4
Control 3–100 21.8 ± 31.1
Hc-CRP after one year
Patients 3–200 29.5 ± 43.4 0.5
Control 3–100 21.8 ± 31.1
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Sensitivity and speciﬁcity of CRP at baseline was 65% and
70%, respectively. Positive predictive value and negative pre-
dictive value was 0.1 and 0.4, respectively. While sensitivity
and speciﬁcity of CRP, after one year, was 50% and 70%,
respectively. Positive predictive value and negative predictive
value was 0.8 and 0.3, respectively.
Sensitivity and speciﬁcity of HA at baseline was 42% and
100%, respectively. Positive predictive value and negative pre-
dictive value was 1 and 0.7, respectively. While sensitivity and
speciﬁcity of HA, after one year, was 38% and 100%, respec-
tively. Positive predictive value and negative predictive value
was 1 and 0.4, respectively.
Sensitivity and speciﬁcity of COMP at baseline was 70%
and 80%, respectively. Positive predictive value and negative
predictive value was 0.9 and 0.5, respectively. While sensitivity
and speciﬁcity of COMP, after one year, was 57% and 80%,
respectively. Positive predictive value and negative predictive
value was 0.9 and 0.8, respectively.
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Adiagnosis of knee OA is traditionally based upon weight bear-
ing radiographs and pain. The diagnosis is usually made by the
time joint tissue degeneration is already advanced. Therefore,
much attention has been focused on developing assays for
molecular markers, namely cartilage derived macromolecules
or their fragments whose release into the circulation from the
jointmay reﬂect disturbances in joint tissue turnover [13]. A par-
ticular need has been to develop markers to sensitively predict
early initiation and progression of OA [5].
There have been a number of reports demonstrating associ-
ations between biochemical markers measured in serum and
disease severity and outcome in OA [14–16].
So this study was designed to evaluate diagnostic and prog-
nostic value of some biochemical markers; hs-CRP, HA and
COMP, in the included patients had early OA knees and their
relation to disease severity and progression.
As regards the radiological evaluation K–L grading score
was done at baseline evaluation but not after one year as for
one patient to progress from one grade K–L to another it
needs more than two years. Thomas score was used at baseline
and after one year as it can detect minute changes that may
progress in one year follow-up. One of the potential uses of
biochemical markers would be to identify patients at high risk
of rapidly progressive joint destruction.
Initial results showed that the older the patient, the higher
the frequency of synovitis and the higher the radiological
grade.
Traditionally CRP has been seen as normal in OA. Sensi-
tive assays show that it is raised in many OA patients, but is
below the level usually detected in hospital clinical pathology
departments [17,15,16]. This agrees with our results as qualita-
tive hs-CRP was signiﬁcantly higher in patients compared to
controls (p= 0.009).
Sharif et al. [18] found that sensitivity and speciﬁcity for
CRP was 38% and 85%, respectively, this is close to the ﬁgures
obtained in our results as sensitivity and speciﬁcity of CRP at
baseline was 65% and 70%, while sensitivity and speciﬁcity of
CRP, after one year, was 50% and 70%. So, serum CRP is not
a good predictor of individual patient progression and has a
poor sensitivity and speciﬁcity.
HA is a marker of synthesis activity of synovium. As a ma-
jor product of synovial cells, HA is considered a marker of
synovitis [13].Our results support that HA at baseline was sig-
niﬁcantly correlated with morning stiffness and joint swelling
(p= 0.1, 0.2), respectively. So HA can be considered a marker
of synovial inﬂammation as it is correlated with joint synovitis
and morning stiffness which reﬂects joint inﬂammation too.
Sharif et al. [18] found that sensitivity and speciﬁcity for HA
was 80% and 89%, respectively. Our results showed that sen-
sitivity of HA is poor (42% at baseline and 38% after one
year), but on contrary it showed high speciﬁcity 100%. This
may be attributed to small number of controls who didn’t
show any elevation of serum HA. But we can say that HA is
a unique marker for joint disease difﬁcult to be detected in
healthy population.
Turan et al. [19] found signiﬁcant difference betweenHA lev-
els in patients and controls (p= 0.02), and this agrees with our
results, as serum levels of HA at baseline and after one year were
signiﬁcantly higher than those of control group (p> 0.001).Also, there was a signiﬁcant correlation between HA level and
disease duration (p= 0.04), ESR (p= 0.001), and CRP level
(p< 0.001), but these items were not correlated in our study.
Turan et al. [19] found signiﬁcant correlation with radiolog-
ical grade (p> 0.05). Elliott et al. [20] came to the same results
that levels of serum HA were positively associated with all def-
initions of radiographic OA (p< 0.0001). Pavelka et al. [6]
found that the patients with higher basic serum levels of HA
had a faster radiological progression (r= 0.56, p< 0.005),
which agrees with our study as the qualitative HA at baseline
was correlated with K–L grading (p= 0.02). We can consider
HA marker of joint destruction and disease progression.
Pavelka et al. [6] found that higher serum levels of COMP
(p= 0.05) were detected compared with healthy control sub-
jects, indicating increased cartilage turnover in OA patients.
That result coincides with ours. Comparing COMP levels at
baseline and after one year in patients and controls revealed
signiﬁcantly higher levels in patients (p> 0.001). These ﬁnd-
ings support the role of COMP as joint marker which is difﬁ-
cult to be elevated in healthy subjects.
Wisowska and Jabon´ska [21] found that the average value
of COMP in OA patients was 10.4 ± 2.7 U/l. This agrees with
our study in which the mean was 16.2 ± 6.3. They found no
correlation between the serum COMP level and patients’ age
and disease duration, and this also agrees with our results. Be-
cause some patients have cartilage destruction early in the dis-
ease and those patients who will progress radiologically, and
others have stationary course that are called non-progressors.
This occurs independent of age or disease duration.
Vilim et al. [5] studied COMP levels in a group of OA pa-
tients; their results didn’t show correlation of COMP levels
with any demographic, clinical, radiological or other labora-
tory parameters at baseline evaluation.
Vilim et al. [5] found a signiﬁcant correlation of serum
COMP levels with a change in JSW over three years. The asso-
ciation was signiﬁcant for COMP level at the study end
(p> 0.001), but not for COMP level at baseline. Clark et al.
[22] observed an association between serum COMP level and
knee OA disease severity assessed by Kellgren and Lawrence
grading. Both are in agreement with our results, as COMP ti-
ters after one year correlated with lateral compartment affec-
tion (p= 0.05) and with Thomas score after one year
(p= 0.007). In some studies, the progression of joint space
narrowing seems to be positively correlated with markers of
degeneration of type I and type II collagen, COMP corre-
sponding to degradation of non-agrecan and non-collagen
proteins [23]. So, serum COMP has the potential to be a prog-
nostic marker of disease progression. Although COMP is ex-
pressed by other tissues within a joint [24], it prevails in the
articular cartilage and it has been demonstrated that serum
levels are representative of cartilage catabolism [25].
Most studies in recent years could draw the conclusion that
COMP was associated with OA. COMP was the foremost bio-
marker among investigated biomarkers. It could be continu-
ously expressed and predicted knee OA progression early
[26]. Thus, the correlation of serum COMP level with Thomas
score as a measure of radiological destruction which reﬂects
cartilage catabolism is accepted.
In the present study, COMP level at baseline were signiﬁ-
cantly correlated with synovitis after one year (p= 0.02)
which was consistent with the results of Vilim et al. [27],
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ing, COMP is known as cartilage marker and its correlation
with synovitis may reﬂect its role in synovial inﬂammation.
Because of the complex involvement of bone, cartilage, syn-
ovium and systemic inﬂammation, only a combination of sev-
eral biochemical markers will adequately predict disease
progression [28].
In our study we found no correlation of serum COMP level
at baseline and at the study end with NRSP or with WOMAC
index, this was consistent with that of Vilim et al. [5]. So we
can say that COMP levels are not a reﬂection to the clinical
or functional status of patients in time of assay, as it may
reﬂect ongoing early cartilage destruction not detectable by
functional parameters. Bruyere et al. [29] could not ﬁnd corre-
lation between baseline levels of COMP and WOMAC index
and that agrees with our results.
On contrary, Wisowska and Jabon´ska [21] found correla-
tion between the serum COMP level and WOMAC index
(p< 0.005), but these parameters were not correlated in our
study at baseline or after one year.
In general it was found from this study and the previous
studies that the best correlation between COMP level and
radiological progression when both knees were included in
the analysis. This result is expected for a marker, such as
COMP, whose potential release from all joints in the body con-
tributes to the serum level [5].
Indeed, clinical indices such as pain and physical function
scores are poorly related to the destruction of joint structure,
as conﬁrmed in our study by the absence of a correlation be-
tween the total WOMAC index and radiological parameters.
To obtain an accurate estimation of the rate of joint pro-
gression of joint destruction in individual patients with early
knee OA, long-term studies are required because of low rate
of progression in patients with established OA.
In this follow-up study we correlated the levels of biochem-
ical markers with radiological destruction using the compart-
mental evaluation of Thomas score. To our knowledge, we
could not ﬁnd other studies using this score with biochemical
markers.
Most previous reports, including the most recent ones, cor-
relating levels of biochemical markers with the degree of joint
destruction, were evaluated by a composite index such as K–L
grading system.
Although the number of patients was small owing to the
cost of biochemical markers; however, this is probably one
of the largest studies performed including both a panel of re-
cently developed biochemical markers and sensitive radiologi-
cal measure. To our knowledge this may be the ﬁrst follow-up
study done on Egyptian OA patient with this design.
In conclusion, the measurements of serum HA and COMP
may be of diagnostic and prognostic value in differentiating pa-
tients with early joint destruction and in determining disease
progression. A single biochemical marker has deﬁnitive diag-
nostic value and the combination with other biochemical mark-
ers as well as with clinical and radiographic data would most
likely help to improve the clinical assessment of patients affected
early with this common disorder. Serum HA was the most spe-
ciﬁc markers with the highest positive predictive value. Serum
hs-CRP is not a good predictor of individual patient progression
and has a poor sensitivity and speciﬁcity. Using the compart-
mental evaluation of Thomas score with biochemical markersis better than K–L grading system especially with short dura-
tions of follow-up.
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